Recent Trends of Helicobacter pylori Eradication Therapy: Focusing on First Line Treatment.
10.7704/kjhugr.2014.14.4.237
- Author:
Ki Bang KIM
1
;
Yong Sik KIM
Author Information
1. Department of Internal Medicine, Eulji University College of Medicine, Daejeon, Korea. ykim0114@gmail.com
- Publication Type:Review
- Keywords:
Helicobacter pylori;
Eradication
- MeSH:
Amoxicillin;
Bismuth;
Clarithromycin;
Diagnosis;
Helicobacter pylori*;
Korea;
Lymphoma;
Peptic Ulcer;
Proton Pumps;
Stomach Neoplasms
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2014;14(4):237-241
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Helicobacter pylori infection causes peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid-tissue lymphoma. H. pylori eradication has played a major role in the prevention and treatment of these diseases. The guidelines for the diagnosis and treatment of H. pylori infection in Korea recommends standard triple therapy consisting of proton pump inhibitor, clarithromycin and amoxicillin as the first line eradication therapy and quadruple therapy including bismuth in case of clarithromycin-resistant H. pylori infection. However, the eradication rate of conventional first line therapy of H. pylori infection has been decreasing during the last decade. Recently the eradication rates of standard triple therapy in Korea is reported to be lower than 80% and sometimes even lower than 70% (intention-to-treat). Therefore, the need for new first line eradication regimens has been rising. Sequential therapy, concomitant therapy and tailored therapy have been introduced as new options for first line therapy. However, they have yet to be proven as standard therapy and need further studies.
